Roger Cady, MD, Lundbeck Pharmaceutical, shares the findings from the RELIEF study (NCT04152083) of eptinezumab initiated during a migraine attack. Eptinezumab is a calcitonin gene-related peptide (CGRP)-targeting monoclonal antibody approved for the preventive treatment of migraine. To investigate the benefits of eptimezumab administered during a migraine attack, the randomized, placebo-controlled trial enrolled patients with 4-15 migraine days per month and randomized patients 1:1 to receive eptinezumab or placebo within 1-6 hours of migraine onset. Time to headache pain freedom and time to absence of most bothersome symptom (MBS) were assessed as the co-primary endpoints. The results from over 450 patients showed that eptinezumab treatment led to significantly faster headache pain freedom and absence of MBS compared to placebo. Eptinezumab treated patients also used significantly less acute medication compared to patients receiving placebo. All seven pre-specified primary and secondary endpoints were met. This interview took place during the European Academy of Neurology 2021 congress.